ASH Clinical News

A magazine from @ASH_Hematology offering news and views for the broader hematology/oncology community.

[ASH Clinical News @ASHClinicalNews]

The June issue is out now! Highlights include articles on the delayed diagnosis of #bleeding disorders in #women, #aspirin use in #pregnant patients with #SCD, microbiome wellness in #hematology, and more. See the full issue lineup here: https://t.co/PBWqphh90x

[ASH Clinical News @ASHClinicalNews]

New research shows that liquid biopsy offers fast, highly accurate molecular diagnosis of EBV-positive #Burkitt #lymphoma and returned a diagnosis 40.3 days sooner than tissue biopsy in resource-limited settings, indicating that it may be a viable tool: https://t.co/lQ3xocYSdp

[ASH Clinical News @ASHClinicalNews]

Therapy-Related AML Rising: The annual incidence of treatment-related acute #myeloid #leukemia (tAML) has increased. According to a study, the annual tAML incidence increased from 0.13 to 0.36 per 100,000 population during the 30-year study period.

[Wiley Clinical and Health @WileyHealth]

Editor-in-Chief Bethany Samuelson Bannow, MD, MCR, shares highlights from the July 2026 issue of @ASHClinicalNews 📑

🔗➡️ https://t.co/1GdDnnRoAb

@bsamuelson_md
@ASH_hematology

[ASH Clinical News @ASHClinicalNews]

The July issue is out now! Special highlights include a feature on the outcomes of consortia-based research, recent abstracts presented as #ASCO26 and #EHA26, the intersection of #hematology and space exploration, and more. See the full issue here: https://t.co/iNzzWQ0I3l

[ASH Clinical News @ASHClinicalNews]

According to phase II findings, the combination of BV plus nivolumab with doxorubicin and dacarbazine produced strong responses in patients with early-stage, non-bulky classical #Hodgkin #lymphoma, resulting in a 96% ORR, 92% CR, and two-year PFS of 97%: https://t.co/CsS4DnVMSc

[ASH Clinical News @ASHClinicalNews]

Cuts Create Consequences: Proposed Affordable Care Act #ACA rules from the Trump administration could lower monthly premiums but increase deductibles. The new rules would allow #deductibles up to $15,000 for individuals and $31,000 for families.

[ASH Clinical News @ASHClinicalNews]

#EHA26 A potential new treatment option, #bezuclastinib was found to produce favorable activity in patients with advanced systemic #mastocytosis, reducing bone marrow mast cell burden, serum tryptase levels, and KIT D816V VAF by more than 50% in most: https://t.co/8T2hmE8ikJ

[ASH Clinical News @ASHClinicalNews]

#EHA26 In older patients with newly diagnosed, NPM1- and IDH1/2-mutated acute myeloid #leukemia #AML, a 28-day regimen of #venetoclax plus #azacitidine had greater efficacy than the standard 14-day regimen, producing CR rates of 61% vs. 33%: https://t.co/xNExbYkDXF

[ASH Clinical News @ASHClinicalNews]

Barriers Beyond Willpower: People with #cancer may face barriers to adopting healthy lifestyle behaviors, such as diet and exercise. An analysis found that lack of energy (58.7%) and physical limitations (52%) are the most common barriers.

[ASH Clinical News @ASHClinicalNews]

Compared with #rivaroxaban, patients with acute #venous #thromboembolism #VTE who were treated with #apixaban had a more than 50% lower rate of clinically relevant bleeding at 3.3% vs. 7.1%, according to recent findings from the COBRA trial: https://t.co/BwLi6TVwlk

[ASH Clinical News @ASHClinicalNews]

Patients with R/R #MMsm #myeloma who responded to #linvoseltamab continued to experience improvements in their symptoms, function, and general health status for up to two years, with overall improvements occurring on all health-related QOL scales: https://t.co/vWUzhk7Mci

[ASH Clinical News @ASHClinicalNews]

#EHA26 In patients with #myelofibrosis, treatment with the anti-hemojuvelin antibody DISC-0974 improved #anemia and reduced #transfusion burden irrespective of JAK inhibitor use, with an overall major and minor response of 70% seen across study cohorts: https://t.co/NI8e96UYnm

[ASH Clinical News @ASHClinicalNews]

#EHA26 In older patients with advanced-stage classic #Hodgkin #lymphoma, treatment with BrECADD using a PET-guided strategy resulted in long-term disease control with lower rates of relapse and progression, achieving a CR of 82% and 3-year PFS of 83.2%: https://t.co/z46YodBRb4

[ASH Clinical News @ASHClinicalNews]

When #AI Misjudges: #ChatGPT Health may not be reliable for determining the several of medical emergencies. A study found that ChatGPT Health under-triaged 51.6% of emergency cases, recommending patients a see doctor in 24-48 hours rather than visiting the emergency room.

[ASH Clinical News @ASHClinicalNews]

In patients with newly diagnosed #MultipleMyeloma #MMsm who were ineligible for ASCT, up-front treatment with #BCMA #CARTcell therapy was found to produce deep and durable responses, with a 100% MRD negativity rate at month 3 and CR in 94.4% of patients: https://t.co/d1CsnJQL4Y

[ASH Clinical News @ASHClinicalNews]

Despite having comparable grit and resilience, hematologists specializing in #SickleCellDisease care were found to experience significantly higher rates of #burnout compared with other physicians, at 60% vs. 44%, and expressed less job pride (47% vs. 65%): https://t.co/BC4dXUgJf4

[ASH Clinical News @ASHClinicalNews]

A secondary analysis from the SWOG S0016 trial has revealed that a subset of patients with advanced-stage #follicular #lymphoma can achieve a cure with CHOP-based #chemoimmunotherapy, showing a 15-year OS 70% with an estimated overall cure rate of 42%: https://t.co/nybbHNDPvw

[ASH Clinical News @ASHClinicalNews]

In pregnant patients with #SCD, low-dose #aspirin was not beneficial in preventing adverse pregnancy outcomes and increased sickle cell-related complications compared with placebo, despite being considered generally safe for #pregnancy: https://t.co/3ibxvqr9Ri
#WorldSickleCellDay

[ASH Clinical News @ASHClinicalNews]

#ASCO26 In a new analysis with 3+ years of follow-up, fixed-duration monotherapy with #glofitamab for R/R #MantleCellLymphoma continued to demonstrate strong responses, with an ORR at 82%, CR at 77%, and a median duration of CR of 40.8 months: https://t.co/x5vGhNImOU

[ASH Clinical News @ASHClinicalNews]

#ASCO26 Compared with SOC combination therapy, #teclistamab monotherapy prolonged survival and improved length and depth of response among patients with R/R #MMsm who had received 1-3 prior lines of therapy, producing an 18-month PFS of 69.8% vs. 26.9%: https://t.co/AuG5wehfIF